MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fonc.2026.1795498

Медицинская библиотека · Frontiers in oncology · 2026

Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study.

Wang Zishuo, Xu Xiaodong, Lv Pengwei, Zhang Jianxiang

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Eribulin is a microtubule inhibitor indicated for metastatic breast cancer (MBC). Previous studies have demonstrated its overall survival benefit in patients with MBC, but data on its efficacy in those with liver metastases are lacking.

METHODS

We retrospectively analyzed the efficacy and safety of eribulin in 73 patients with liver metastases from breast cancer treated at the First Affiliated Hospital of Zhengzhou University between 2020 and 2024. Systemic progression-free survival and objective response rate were assessed per RECIST version 1.1, and adverse events were evaluated.

RESULTS

The median progression-free survival was 3.7 months (95% CI: 2.8-4.6), with a systemic objective response rate of 15.1% (95% CI: 7.8%-25.4%; partial responses only). The highest objective response rate (21.2%) was numerically observed in the HR+/HER2- subtype. The most common adverse events were neutropenia (42.5%), fatigue (37.0%), alopecia (34.2%), and peripheral neuropathy (28.8%), with no treatment-related deaths.

CONCLUSIONS

In this single-center retrospective exploratory analysis, eribulin-based therapy demonstrated preliminary activity in heavily pre-treated breast cancer patients with liver metastases. These hypothesis-generating findings warrant further prospective validation.

Для цитирования: Wang Zishuo, Xu Xiaodong, Lv Pengwei, Zhang Jianxiang. Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study.. Frontiers in oncology. 2026. DOI: 10.3389/fonc.2026.1795498.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.